AI Technology Group Inc. acquires AVM Biotechnology Inc. (2025)

Deal facts

Buyer: AI Technology Group Inc.
Target: AVM Biotechnology Inc.
Deal value: Not disclosed
Announced: 15 December 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares

Sources

SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

15 Dec 2025CompletedClosed
AI Technology Group Inc. completes acquisition of AVM Biotechnology Inc.
Item 2.01 to amend its Convertible Debentures amounted to $1,587,00, an increase of $462,000, convertible into 634,800 common shares of the Corporation, an increase of 50,000 shares of common stock. Item 1.01 – Entry into a Material Definitive Agreement On December 15, 2025, AI Technology Group Inc. (the “Corporation”) entered into a Share Exchange Agreement as amended hereto with AVM Biotechnolog
Source

OpinionExit Mode editorial

We see a strategic acquisition in the healthcare sector that shifts the balance of power for technology-driven biotech firms. AI Technology Group Inc. has completed its acquisition of AVM Biotechnology Inc. on 15 December 2025. The deal structure is notable because the entire consideration is paid in shares. This is not a cash exit for the founders of AVM Biotechnology. Instead, they remain exposed to the market performance of the combined entity. For the SME founder reading this, the choice to accept shares rather than cash signals a long-term bet on the buyer's ability to integrate and scale the technology.

The cross-border nature of this transaction between two US entities simplifies the regulatory landscape compared to a UK or EU deal, yet the sector remains heavily scrutinised. Healthcare acquisitions always invite attention from competition authorities and sector-specific regulators. While the deal is marked as completed, the integration phase now carries the weight of change-of-control covenants that often trigger in share-based deals. These covenants can restrict the operational autonomy of the acquired team and alter key personnel contracts. The absence of a disclosed value in the announcement is typical for share-swap transactions where the final valuation fluctuates with the stock price until the closing date.

We think the use of a pure share consideration mechanism places the risk of post-close volatility squarely on the seller. In a cash deal, the founder walks away with certainty. Here, the founder's wealth is tied to the buyer's share price movement from the announcement date through to the actual settlement. This structure often serves as a retention tool, binding the target leadership to the new group's success. It also suggests the buyer may be conserving cash for R&D or integration costs, which is a common tactic in the biotech space. The strategic logic appears to be the absorption of specific AI capabilities within a biotech framework rather than a simple financial buyout.

You must review the lock-up period and vesting schedule attached to the shares you received in any similar transaction this week. Do not assume the shares are immediately liquid or that you can sell them without restriction. Check the specific terms regarding the release of your holdings and the conditions under which the buyer can adjust the number of shares issued. Understanding these mechanics is the only way to manage your personal exposure in a share-based exit.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More strategic acquisition deals More from AI Technology Group Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 July 2026CompletedHealthcare

GSK plc to acquire Nuvalent, Inc

GSK plc has agreed to acquire Nuvalent, Inc in a strategic acquisition valued at $10.6 billion. The transaction, announced and completed on 15 July 2026, involves full c…

Buyer: GSK plc
Target: Nuvalent, Inc
Deal value: USD 10,600,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

14 July 2026CompletedHealthcare

Volex plc to acquire Kepler SignalTek Ltd

Volex plc has agreed to acquire Kepler SignalTek Ltd, a healthcare sector business based in the United Kingdom. The strategic acquisition was announced and completed on…

Buyer: Volex plc
Target: Kepler SignalTek Ltd
Deal value: USD 89,400,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

2 July 2026CompletedHealthcare

Lixte Biotechnology Holdings, Inc. to acquire Nomad Transportable Power Systems, Inc.

Lixte Biotechnology Holdings, Inc. has agreed to acquire Nomad Transportable Power Systems, Inc. in a strategic acquisition within the Healthcare sector. The transaction…

Buyer: Lixte Biotechnology Holdings, Inc.
Target: Nomad Transportable Power Systems, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

30 June 2026Firm intentionHealthcare

Public Company Management Corporation to acquire Physicians Capital Management Corporation

Public Company Management Corporation has agreed to acquire Physicians Capital Management Corporation in a strategic acquisition within the healthcare sector. The transa…

Buyer: Public Company Management Corporation
Target: Physicians Capital Management Corporation
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history